STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Purchases 8,221 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the business’s stock in a transaction on Thursday, January 16th. The stock was purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50. Following the acquisition, the insider now owns 10,878,007 shares in the company, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.46 per share, with a total value of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The shares were acquired at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The stock was acquired at an average price of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Trading Up 0.6 %

Shares of STAAR Surgical stock opened at $21.85 on Friday. STAAR Surgical has a 12 month low of $21.13 and a 12 month high of $52.68. The firm has a market capitalization of $1.08 billion, a P/E ratio of 49.66 and a beta of 0.63. The business has a fifty day simple moving average of $25.53 and a two-hundred day simple moving average of $32.09.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of STAA. Geode Capital Management LLC grew its holdings in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after purchasing an additional 31,212 shares during the period. Mutual of America Capital Management LLC boosted its position in shares of STAAR Surgical by 214.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock worth $1,260,000 after purchasing an additional 18,051 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of STAAR Surgical in the 3rd quarter worth approximately $336,000. Algert Global LLC increased its position in STAAR Surgical by 13.5% during the 2nd quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier’s stock valued at $5,554,000 after buying an additional 13,901 shares in the last quarter. Finally, Granite Investment Partners LLC purchased a new position in STAAR Surgical during the second quarter valued at $17,237,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on STAA. Stephens upgraded STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Canaccord Genuity Group decreased their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, STAAR Surgical presently has a consensus rating of “Hold” and a consensus price target of $42.83.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.